According to a recent market study published by Growth Market Reports, titled, Global Acute Dystonia Market By Drug Class, Age, Distribution Channel, and Region: Size, Share, Trends and Opportunity Analysis, 2016-2031, the market was valued at USD 116.17 Million in 2022 and is anticipated to expand at a growth rate of 3.3% by 2031.

Get Sample Report @ https://growthmarketreports.com/request-sample/6195

Acute dystonia is a movement disorder that is characterized by involuntary muscle contractions. It is a side effect of certain medications, such as antidopaminergic agents. The symptoms of acute dystonia include atypical posture or position of muscles, which occurs within a few days of taking these medications.

Dystonia is a movement disorder that causes the muscles to contract involuntarily. This causes repetitive or twisting movements. The condition affects one part of the body (focal dystonia), two or more adjacent parts (segmental dystonia), or all parts of the body (general dystonia). The muscle spasms range from mild to severe and are painful, interfering with daily tasks.

There is no cure for dystonia; however, medications and therapy help improving symptoms. Surgery is sometimes used to disable or regulate nerves or certain brain regions in people with severe dystonia. The global acute dystonia market has been segmented in terms of drug class, age, distribution channel and region. In terms of drug class, the global acute dystonia market is split into anticholinergic agents, benzodiazepines, and others.

Based on age, the market is divided into childhood onset (0 to age 12) adolescent onset (age 13 to 20), and adult onset (older than age 20). In terms of distribution channel, the market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. In terms of region, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

The COVID-19 pandemic had a considerable impact on various markets, including the acute dystonia market. The COVID-19 disease induces serious respiratory diseases. Symptoms increased with detrimental consequences for job and daily functionality of patients. Outpatient clinics and rehabilitation sessions were temporarily shut down during the pandemic.

Key Takeaways from the Study:

  • Players in the global acute dystonia market include Fresenius Kabi, Hikma Pharmaceuticals PLC, Merit Pharmaceutical, Par Pharmaceutical, Inc, Viatris Inc, and Zydus Pharmaceuticals, Inc. These players held a considerable share of the global acute dystonia market in 2022.

  • Growing Use of various neuroleptic drugs causing dyskinesia among the patients is key factor that is driving the acute dystonia market.

  • Emerging Markets such as China & India are expected to create opportunities in the coming years.

  • Based on drug class, the market is segmented into anticholinergic agents, benzodiazepines, and others. The anticholinergic agents segment is expected to hold a significant share of the market during the forecast period, as it is widely used for the first line treatment for acute dystonic reaction treatment.

  • Based on the age, the market is segmented into childhood onset (0 to age 12), adolescent onset (age 13 to 20), and adult onset (older than age 20). The adult onset (older than age 20) segment is anticipated to expand at a significant CAGR during the forecast period, owing to the increased intake of several medicines that is increasing risks for acute dystonia during the forecast period.

  • Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Europe accounted for a significant share of the market in 2022, due to the increased acute dystonia cases in the region.

  • In 2021, the UK ranked fourth highest across the globe in terms of healthcare spending as a share of GDP. Germany, which spent 12.8% of its GDP on healthcare, ranked first in the same year. Factors such as an aging population and rising healthcare costs are expected to contribute to the high demand for acute dystonia drugs in the region during the forecast period.

Acute Dystonia Market Report Scope:

Report Metric

Details

Market Value in 2022

USD 116.17 Million

Market Growth Rate (from 2022 to 2031)

3.3%

Historical Data

2016 & 2021

Base Year

2022

Forecast Period

2023 – 2031

Units Considered

Value (USD Million)

Market Segments

By Drug Class, Age, Distribution Channel, and Region

Key Companies Profiled

Fresenius Kabi, Hameln Pharma Gmbh, Hikma Pharmaceuticals PLC, Merit Pharmaceutical, Par Pharmaceutical, Inc, Ryvis Pharma, Viatris Inc, Zydus Pharmaceuticals, Inc, and Others

Customization Scope

Report customization available on request

Pricing and Purchase Options

Avail of tailor-made purchase options to meet your research requirements.

Target Audience:

  • Supply-side: Vendor, manufacturer, distributors, supplier, and retailer

  • Regulatory Side: Concerned government authorities, and other approved regulatory bodies.

  • Food and Drug Administration (FDA)

  • The Organization for Economic Cooperation and Development (OECD)